Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $25.12 -4.88%
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
- General Mills (GIS) Tops Q1 EPS by 3c
- Worthington Industries (WOR) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
